Safety and efficacy of hematopoietic stem cells mobilization in patients with multiple sclerosis

Hematology
Sławomira Kyrcz-KrzemieńMałgorzata Krawczyk-Kuliś

Abstract

Multiple sclerosis (MS) is a T-cell-mediated chronic inflammatory disorder of the central nervous system. Several agents have been approved for treatment of MS, however their efficacy is limited and short term. Autologous hematopoietic stem cell (HSC) transplantation may remain an encouraging option for some MS patients who failed prior conventional treatment. To assess the safety and effectiveness of HSCs mobilization in patients with MS. Thirty-nine patients (20 females, 19 males) with relapsing-remitting MS at median age of 40 years (range 25-63) were included in this study. As a stem cell mobilization they received either granulocyte colony-stimulating factor (G-CSF) alone (10 μg/kg s.c. daily; n = 1) or cyclophosphamide (CY; 2.0 g/m(2) i.v. on days 1-2) followed by G-CSF (n = 38). The median number of mobilized HSCs per kilogram was 6.32 × 10(6) (range 2.64-26.3 × 10(6)). One apheresis was sufficient for collection of HSCs in 30 out of 39 MS patients (77%). Two aphereses were required for seven patients, three for one patient, and four for one patient (17, 3, and 3%, respectively). Side effects of HSCs mobilization have been reported for eight patients (30%) and they were as follows: Staphylococcus epidermidis bacteremia (...Continue Reading

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.